Robert H. Bradbury

2.0k citations

34 papers · 623 indexed · h-index 15

Co-authors: Neil J. Hales John S. Major Peter Ballard Timothy Gallagher Michael Robert Dennis Donald Ogilvie Teresa Klinowska Jason G. Kettle
Topics: Quinazolinone synthesis and applications (8 papers)Synthesis and Biological Evaluation (8 papers)HER2/EGFR in Cancer Research (7 papers)
Cited by: Organic Chemistry Oncology Computational Theory and Mathematics
Journals: Journal of the American Chemical Society Cancer Research Journal of Medicinal Chemistry
Partner nations: United Kingdom France United States

In The Last Decade

Robert H. Bradbury

34 papers receiving 584 citations

Peers

Countries citing papers authored by Robert H. Bradbury

Since Specialization

Citations

This map shows the geographic impact of Robert H. Bradbury's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H. Bradbury with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H. Bradbury more than expected).

Fields of papers citing papers by Robert H. Bradbury

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H. Bradbury. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H. Bradbury. The network helps show where Robert H. Bradbury may publish in the future.

Co-authorship network of co-authors of Robert H. Bradbury

This figure shows the co-authorship network connecting the top 25 collaborators of Robert H. Bradbury. A scholar is included among the top collaborators of Robert H. Bradbury based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert H. Bradbury. Robert H. Bradbury is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models 2016 ·Cancer Research ·Lenka Oplustil O’Connor,Stuart L. Rulten,Aaron Cranston,Rajesh Odedra,H. Shelton Brown,Janneke E. Jaspers,(unknown),Charlotte Knights,Bastiaan Evers,Attilla Ting,Robert H. Bradbury,Marina Pajic,Sven Rottenberg,Jos Jonkers,(unknown),Niall M.B. Martin,Keith W. Caldecott,Alan Lau,Mark J. O’Connor	60
2	A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs) 2015 ·SLAS DISCOVERY ·Rowena Callis,Alfred A. Rabow,Michael Tonge,Robert H. Bradbury,Mairi Challinor,Karen Roberts,Karen L. Jones,Graeme E. Walker	22
3	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors 2013 ·ACS Medicinal Chemistry Letters ·Bernard Barlaam,Judith Anderton,Peter Ballard,Robert H. Bradbury,Laurent Hennequin,D. Mark Hickinson,Jason G. Kettle,(unknown),Teresa Klinowska,Christine Lambert‐van der Brempt,Cath Trigwell,John P. Vincent,Donald Ogilvie	31
4	Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer 2011 ·Bioorganic & Medicinal Chemistry Letters ·Robert H. Bradbury,Neil J. Hales,Alfred A. Rabow,Graeme E. Walker,David Acton,David Andrews,Peter Ballard,Nigel Brooks,Nicola Colclough,(unknown),Urs J. Hancox,Owen D. Jones,David A. Jude,Sarah A. Loddick,Andrew Mortlock	36
5	Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2008 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam,David Acton,Peter Ballard,Robert H. Bradbury,Darren A.E. Cross,Richard Ducray,(unknown),Kevin Hudson,Teresa Klinowska,(unknown),Donald Ogilvie,Annie Olivier,(unknown),(unknown),Cath Trigwell,(unknown),(unknown)	10
6	1 Topics in Medicinal Chemistry 2007 ·Robert H. Bradbury	4
7	Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2007 ·Bioorganic & Medicinal Chemistry Letters ·Peter Ballard,Bernard Barlaam,Robert H. Bradbury,Allan Dishington,Laurent Hennequin,D. Mark Hickinson,(unknown),Jason G. Kettle,Teresa Klinowska,Donald Ogilvie,Stuart E. Pearson,James S. Scott,Abid Suleman,(unknown),Emma Williams,Robin Wood,(unknown)	23
8	A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2007 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam,Peter Ballard,Robert H. Bradbury,Richard Ducray,(unknown),D. Mark Hickinson,Kevin Hudson,Jason G. Kettle,Teresa Klinowska,(unknown),Donald Ogilvie,Annie Olivier,Stuart E. Pearson,James S. Scott,Abid Suleman,Cath Trigwell,(unknown),(unknown),Robin Wood	18
9	Inhibitors of epidermal growth factor receptor tyrosine kinase: Optimisation of potency and in vivo pharmacokinetics 2006 ·Bioorganic & Medicinal Chemistry Letters ·Peter Ballard,Robert H. Bradbury,Craig S. Harris,Laurent Hennequin,(unknown),Jason G. Kettle,Jane Kendrew,Teresa Klinowska,Donald Ogilvie,Stuart E. Pearson,Emma Williams,(unknown)	29
10	5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase 2005 ·Bioorganic & Medicinal Chemistry Letters ·Peter Ballard,Robert H. Bradbury,Laurent Hennequin,D. Mark Hickinson,Paul D. Johnson,Jason G. Kettle,Teresa Klinowska,Rémy Morgentin,Donald Ogilvie,Annie Olivier	31
11	Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket 2005 ·Bioorganic & Medicinal Chemistry Letters ·Peter Ballard,Robert H. Bradbury,Craig S. Harris,Laurent Hennequin,(unknown),Paul D. Johnson,Jason G. Kettle,Teresa Klinowska,Andrew G. Leach,Rémy Morgentin,Martin Pass,Donald Ogilvie,Annie Olivier,Nicolas Warin,Emma Williams	31
12	New Non-Peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure−Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl-, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides 1997 ·Journal of Medicinal Chemistry ·Robert H. Bradbury,(unknown),Roger J. Butlin,Michael Robert Dennis,(unknown),(unknown),Roger F.L. James,Andrew Mortlock,(unknown),Eric Tang,(unknown),(unknown),Campbell Wilson	23
13	New nonpeptide angiotensin II receptor antagonists. 3. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)pyridine derivatives 1993 ·Journal of Medicinal Chemistry ·Robert H. Bradbury,(unknown),Michael Robert Dennis,(unknown),Peter W. Kenny,John S. Major,(unknown),Arnold H. Ratcliffe,(unknown)	58
14	Quinoline, 1,5-naphthyridine and pyridine derivatives as potent, nonpeptidic angiotensin II receptor antagonists 1993 ·Bioorganic & Medicinal Chemistry Letters ·(unknown),Robert H. Bradbury,Michael Robert Dennis,Eric F. Fisher,Richard Luke,John S. Major,(unknown),(unknown),(unknown),David A. Roberts,(unknown),(unknown)	8
15	2-Amino ketene S,S-acetals as α-amino acid homoenolate equivalents. Synthesis of 3-substituted prolines and molecular structure of 2-(N-pivaloylpyrrolidin-2-ylidene)-1,3-dithiane 1992 ·Journal of the Chemical Society Perkin Transactions 1 ·William O. Moss,(unknown),(unknown),Mary F. Mahon,Kieran C. Molloy,Robert H. Bradbury,Neil J. Hales,Timothy Gallagher	13
16	Ketene S,S-acetals as 1,3-dipolarophiles: application to the synthesis of polyhydroxylated pyrrolidines 1992 ·Journal of the Chemical Society Perkin Transactions 1 ·William O. Moss,Robert H. Bradbury,Neil J. Hales,Timothy Gallagher	9
17	New nonpeptide angiotensin II receptor antagonists. 2. Synthesis, biological properties, and structure-activity relationships of 2-alkyl-4-(biphenylylmethoxy)quinoline derivatives 1992 ·Journal of Medicinal Chemistry ·Robert H. Bradbury,(unknown),Michael Robert Dennis,Eric F. Fisher,John S. Major,Brian B. Masek,(unknown),(unknown),(unknown)	46
18	1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 3. Synthesis and biological properties of aminodeoxystatine and difluorostatone derivatives 1991 ·Journal of Medicinal Chemistry ·Robert H. Bradbury,(unknown)	36
19	1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 1. Synthesis and biological properties of alkyl alcohol and statine derivatives 1990 ·Journal of Medicinal Chemistry ·D. Allen Roberts,Robert H. Bradbury,David Brown,(unknown),David Griffiths,John S. Major,(unknown),(unknown),Arnold H. Ratcliffe	7
20	1,2,4-Triazolo[4,3-a]pyrazine derivatives with human renin inhibitory activity. 2. Synthesis, biological properties and molecular modeling of hydroxyethylene isostere derivatives 1990 ·Journal of Medicinal Chemistry ·Robert H. Bradbury,John S. Major,(unknown),(unknown),David A. Roberts,Anthony M. Slater,David Timms,David Waterson	12

About Robert H. Bradbury

Robert H. Bradbury is a scholar working on Organic Chemistry, Oncology and Pharmaceutical Science, having authored 34 papers that have together received 623 indexed citations. Recurring topics across this work include Quinazolinone synthesis and applications (8 papers), Synthesis and Biological Evaluation (8 papers) and HER2/EGFR in Cancer Research (7 papers). The work is most often cited by research in Organic Chemistry (343 citations), Oncology (153 citations) and Computational Theory and Mathematics (69 citations). Robert H. Bradbury has collaborated with scholars based in United Kingdom, France and United States. Frequent co-authors include Neil J. Hales, John S. Major, Peter Ballard, Timothy Gallagher, Michael Robert Dennis, Donald Ogilvie, Teresa Klinowska, Jason G. Kettle, Laurent Hennequin and William O. Moss. Their work appears in journals such as Journal of the American Chemical Society, Cancer Research and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact